Evidence map›Paper›PMID 28148887›Full record

SynthesisAging2017

MiR-146a and miR-196a-2 polymorphisms are associated with hepatitis virus-related hepatocellular cancer risk: a meta-analysis.

Tian Tian, Meng Wang, Wenge Zhu, Zhi-Ming Dai, Shuai Lin, Peng-Tao Yang, Xing-Han Liu, Kang Liu, Yu-Yao Zhu, Yi Zheng and 2 more

Open access · hybridAbstract readMeta-Analysis
In one paragraph

Synthesis in Aging, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 3 pooled it
1.3field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 3 syntheses or guidelines pooled it, 22 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. The association between theBioscience reports · 2018
    Article
  12. Lack of association betweenBioscience reports · 2018
    Article
  13. Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 2 countries.

Tian TianDepartment of Oncology, Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, China.
Meng WangDepartment of Oncology, Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, China.
Wenge ZhuDepartment of Biochemistry and Molecular Medicine, The George Washington University Medical School, Washington, DC 20037, USA.
Zhi-Ming DaiDepartment of Anesthesia, Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, China.
Shuai LinDepartment of Oncology, Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, China.
Peng-Tao YangDepartment of Oncology, Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, China.
Xing-Han LiuDepartment of Oncology, Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, China.
Kang LiuDepartment of Oncology, Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, China.
Yu-Yao ZhuDepartment of Oncology, Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, China.
Yi ZhengDepartment of Oncology, Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, China.
Meng LiuDepartment of Oncology, Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, China.
Zhi-Jun DaiDepartment of Oncology, Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, China.
George Washington University · USSecond Affiliated Hospital of Xi'an Jiaotong University · CN

Funding

The Role of And-1 in DNA Damage ResponseR01CA177898 · NCI · GEORGE WASHINGTON UNIVERSITY · PI ZHU, WENGE · 2014 to 2018
$1.6M
The Regulation of Cisplatin resistance in ovarian cancerR01CA184717 · NCI · GEORGE WASHINGTON UNIVERSITY · PI ZHU, WENGE · 2014 to 2018
$1.6M
NCI NIH HHS R01 CA177898NCI NIH HHS R01 CA184717
6 · The paper itself

Abstract

Previous studies have investigated the role of miR-146a rs2910164 and miR-196a-2 rs11614913 polymorphisms in hepatocellular carcinoma (HCC) susceptibility, but the results are contradictory and few specifically studied hepatitis virus-related HCC. Therefore, we conducted a meta-analysis to evaluate the association between these two polymorphisms and hepatitis virus-related HCC risk. We performed a systematical search in EMBASE, PubMed, Web of Science, CNKI and Wanfang databases as of 25th November, 2016. Finally, we assessed 14 studies involving 3852 cases and 5275 controls. Our results suggest that rs2910164 has a significant association with increased hepatitis virus-related HCC risk in allelic, homozygous, heterozygous, and dominant models (CG+GG vs. CC: OR=1.22, 95% CI=1.06-1.39, P=0.004), particularly in Chinese and HBV-related HCC subgroups. Conversely, rs11614913 was associated with lower hepatitis virus-related HCC risk in the overall analysis under allelic (T vs. C: OR=0.85, 95% CI=0.74-0.98, P=0.02), homozygous, dominant and recessive models. Subgroup analyses showed decreased risk in Chinese, HBV- and HCV-related HCC. In conclusion, miR-146a C>G (rs2910164) can increase HBV-related HCC risk while miR-196a-2 C>T (rs11614913) may decrease the risk of HBV- and HCV-related HCC, especially in the Chinese population. Further, large-scale studies including other races are required to confirm these findings.

Indexed as

Polymorphism, Single NucleotideCarcinoma, HepatocellularGenetic Predisposition to DiseaseHepatitisHepatitis VirusesHumansLiver NeoplasmsMicroRNAsRisk FactorsMicroRNAsMIRN146 microRNA, humanMIRN196 microRNA, humanhepatitis virus-related hepatocellular carcinomameta-analysismicroRNAsingle nucleotide polymorphism

Identifiers

PMID28148887
PMCPMC5361670
OpenAlexW2584196950

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.